Drug Profile
Pegmolesatide - Jiangsu Hansoh Pharmaceutical
Alternative Names: EPO-018B; HS-20039; Pegol Sihematide - Jiangsu Hansoh Pharmaceutical; Pegsihematide - Jiangsu Hansoh Pharmaceutical; Peihuaxi hippocampal peptide - Jiangsu Hansoh PharmaceuticalLatest Information Update: 14 Mar 2023
Price :
$50
*
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Anti-inflammatories; Antianaemics; Peptides; Polyethylene glycols
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Anaemia
Most Recent Events
- 05 Oct 2021 No development reported - Phase-II for Anaemia (Treatment-experienced) in China (IV) (Jiangsu Hansoh Pharmaceutical website, October 2021)
- 15 May 2019 Phase-III clinical trials in Anaemia (Treatment-experienced) in China (SC) (NCT03902691)
- 04 Apr 2019 Jiangsu Hansoh Pharmaceutical plans a phase III trial for Anaemia in patients with chronic kidney disease on dialysis in China in May 2019 (NCT03902691)